On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development

By Lowe P. J.   Hijazi Y.   Luttringer O.   Yin H.   Sarangapani R.   Howard D.  

Xenobiotica, Vol. 37, Iss. 10-11, 2007-11 ,pp. : 1331-1354

Informa Healthcare

Access to resources Recommend Favorite

Lipoxygenases - A Challenging Problem in Enzyme Inhibition and Drug Development

By  

Current Enzyme Inhibition, Vol. 3, Iss. 2, 2007-05 ,pp. : 119-132

Bentham Science Publishers

Access to resources Recommend Favorite

Aspartic Peptidase Inhibitors: Implications in Drug Development

By Dash Chandravanu   Kulkarni Aarohi   Dunn Ben   Rao Mala  

Critical Reviews in Biochemistry and Molecular Biology, Vol. 38, Iss. 2, 2003-03 ,pp. : 89-119

Informa Healthcare

Access to resources Recommend Favorite

Preclinical and in vitro assessment of the potential of D0870, an antifungal agent, for producing clinical drug interactions

By Mckillop D.   Back D. J.   Mccormick A. D.   Evans J. A.   Tjia J.  

Xenobiotica, Vol. 29, Iss. 4, 1999-04 ,pp. : 395-408

Informa Healthcare

Access to resources Recommend Favorite

Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: A resource for investigations into drug disposition

By Bleasby* K.   Castle* J. C.   Roberts C. J.   Cheng C.   Bailey W. J.   Sina J. F.   Kulkarni A. V.   Hafey M. J.   Evers R.   Johnson J. M.   Ulrich R. G.   Slatter J. G.  

Xenobiotica, Vol. 36, Iss. 10-11, 2006-10 ,pp. : 963-988

Informa Healthcare

Access to resources Recommend Favorite